Initiation of phase 1 portion of the trial planned in 2H 2026 -Phase 2 portion of the trial will initiate development of the elraglusib tablet in specific indications, including refractory melanoma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback